Le Lézard
Classified in: Health
Subjects: CCA, ACC

Invitation to Presentation of Sectra's Three-month Interim Report on September 3, 2019


LINKÖPING, Sweden, Aug. 22, 2019 /PRNewswire/ -- Linköping, Sweden ? August 22, 2019 ? The international medical imaging IT and cybersecurity company Sectra (STO: SECT B) will publish its interim report for the period May to July 2019 on September 3, 2019. Sectra invites analysts, investors, and the media to attend a teleconference/audiocast in conjunction with the publication of the report. 

Publication of the interim report: 8:15 a.m. September 3, 2019 

Presentation and audiocast: 10:00 a.m. September 3, 2019 

To participate, follow online at sectra.com/q1report2019, or call one of the following numbers five to ten minutes before the conference begins: 

SE +46851999383

UK +443333009034

US +18335268380

Sectra management will present the interim report and answer any questions. The presentation will be held in English and a recorded version will be available via sectra.com/q1report2019 after the conference. 

Approximately 30 minutes before the start, a PDF version of the presentation will be available for download. 

Sectra's financial report calendar and annual general meeting 

September 5, 2019 at 3:30 p.m.:  Annual general meeting in Linköping, Sweden
November 29, 2019 at 8:15 a.m.:  Six-month interim report  
March 4, 2020 at 08:15 a.m.:  Nine-month interim report  
June 3, 2020 at 8:15 a.m.:  Year-end report 2019/2020  

Further information about Sectra's financial events and interim reports: investor.sectra.com/events-and-presentations/

Subscribe for information 

To subscribe to financial reports, invitations, and information from Sectra via email, please fill in your contact information at www.sectra.com/subscribe 

About Sectra

Sectra assists hospitals throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society's most sensitive information. Thereby, Sectra contributes to a healthier and safer society. The company was founded in 1978, has its head office in Linköping, Sweden, with direct sales in 19 countries, and operates through partners worldwide. Sales in the 2018/2019 fiscal year totaled SEK 1,413 million. The Sectra share (STO: SECT B) is quoted on the Nasdaq Stockholm exchange. For more information, visit https://sectra.com/.

 For further information, please contact: 
Helena Pettersson
Chief Investor Relations Officer Sectra AB
Ph: 46-13-23-52-04
e-mail [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/invitation-to-presentation-of-sectra-s-three-month-interim-report-on-september-3--2019,c2885898

 

SOURCE Sectra


These press releases may also interest you

at 16:32
The wishes that Make-A-Wish grants wouldn't be possible without the support of countless "WishMakers" such as donors, volunteers, corporate partners, community advocates and more. "WishMakers" ? a term for anyone who steps up to take action...

at 16:30
Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, announced a new appointment to the Canadian Centre on Substance Use and Addiction (CCSA) Board of Directors. Scott Elliott is appointed as...

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...



News published on and distributed by: